Twist Bioscience Co. (NASDAQ:TWST) COO Sells $10,440.11 in Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 229 shares of Twist Bioscience stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $45.59, for a total transaction of $10,440.11. Following the completion of the transaction, the chief operating officer now directly owns 274,466 shares in the company, valued at approximately $12,512,904.94. The trade was a 0.08 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Patrick John Finn also recently made the following trade(s):

• On Monday, November 11th, Patrick John Finn sold 10,340 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total transaction of $496,320.00.
• On Wednesday, November 6th, Patrick John Finn sold 6,239 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total value of $278,259.40.
• On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total value of $111,422.36.
• On Wednesday, October 23rd, Patrick John Finn sold 2,261 shares of Twist Bioscience stock. The shares were sold at an average price of $43.09, for a total transaction of $97,426.49.

Twist Bioscience Stock Performance

NASDAQ:TWST opened at $45.12 on Thursday. The firm has a 50-day simple moving average of $46.26 and a two-hundred day simple moving average of $46.47. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90. The firm has a market cap of $2.68 billion, a P/E ratio of -12.53 and a beta of 1.85.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TWST. Wilmington Savings Fund Society FSB purchased a new stake in shares of Twist Bioscience during the third quarter valued at $34,000. Signaturefd LLC boosted its holdings in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after acquiring an additional 306 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new stake in shares of Twist Bioscience in the second quarter worth approximately $61,000. Beaird Harris Wealth Management LLC purchased a new position in shares of Twist Bioscience during the third quarter valued at approximately $95,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after purchasing an additional 381 shares during the period.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on TWST shares. Wolfe Research began coverage on Twist Bioscience in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price on the stock. Robert W. Baird increased their price objective on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a report on Tuesday, November 19th. TD Cowen restated a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. Evercore ISI increased their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, Barclays dropped their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.